Importantly, Gαi-coupled GPCRs, including cannabinoid receptors 46, CXCR4 47, 48, dopamine D2 receptors 24 and melatonin receptor II (MTII) 49, were reported to be important for glioma progression. The gene discussed is DRD2; the disease is central nervous system cancer.